It’s been a busy few months for Canadian speciality pharmaceutical drug company PharmaDrug Inc.(CNSX: PHRX) (OTCMKTS: LMLLF), as their research into Cepharanthin as a potential cure for COVID has yielded promising results.
The company also made the news yesterday when they announced the addition of world renowned Dr. Cindy Hutnik to their scientific and clinical advisory board.
Dr. Hutnik currently serves as the President of the Canadian Glaucoma Society and also serves as a professor in the Schulich School of Medicine and Dentistry Departments of Ophthalmology and Pathology.
By bringing on the services of a leading voice in the study of glaucoma, PharmaDrug seeks to enhance their continual efforts to treat the disease with N,N-dimethyltryptamine, or DMT.
The ongoing studies are not limited to DMT alone, as PharmaDrug is also exploring similar tryptamine analogues in hopes of developing an eventual cure for the disease that remains the leading cause for blindness for those over 60.
PharmaDrug CEO Daniel Cohen joins The Dales Report to talk about the ongoing research and to update psychedelic investors on the current trajectory of the company in relation to clinical trial results and FDA approval.
Before discussing Dr. Hutnik’s impact on PharmaDrug’s research into DMT and glaucoma, Cohen opens by elaborating on the pre-IND meeting with the FDA and the significance of the pre-clinical trial results.
“We had submitted a proposal for a pre-IND meeting for Cepharanthin in COVID. And we were granted the meeting, they felt that it was legitimate meeting requests. And this type of meeting takes form, and really they basically send you the results of what they think.”
“A pre-IND meeting is like, I’ve used this analogy before, going to the professor two weeks before your essays due and handing in your essay and getting the feedback, not the grade, but the feedback so that when you finally hand it in, you can hand in something better, and have a better expectation of what’s going to be the outcome. So that was the point of the pre-IND or that is the point of a pre-IND meeting.”
“Despite the fact that it was a pre-IND meeting requests for Cepharanthin and COVID, it actually has significant impacts in us planning and moving forward for Cepharanthin in general, and Cepharanthin in cancer as well. Because of that, we will not need a pre-IND meeting for Cepharanthin and cancer.”
“So when they’re looking at this, the FDA, they’re looking at two different aspects, the COVID aspect of Cepharanthin, but then Cepharanthin itself, our version of Cepharanthin as a drug that can be manufactured, because you can say that it has efficacy, but you have to know that you can produce this drug, GMP, industrial scale, you know, pharmaceutical caliber, and, you know, mass production, right. And so you have to show your ability to do that, or else it’s just a theoretical exercise. And so, you know, there are many different aspects.”
The interview sees Cohen dive deeper into the company’s clinical trials and PharmaDrug’s ongoing efforts to get a product to market. But while psychedelics might garner the headlines, Shadd shifts gears to discuss Germany’s recent move to legalize cannabis.
The announcement is relevant for PharmaDrug, as the company also produces a number of THC oils. Germany’s news also sees Cohen announce that PharmaDrug might once again look to flower products as demand is expected to increase.
Both cannabis and psychedelic investors will find this interview to be of great interest, as PharmaDrug has managed to co-exist in both industries while maintaining its reputation as an industry leader.
Join Dales and Cohen for this exclusive look into the world of drug development, from concept to the finished product.